Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 28, 2006

View Archived Issues

Snapshots of newly reported clinical trials in leukemia, myelodysplastic syndromes: I

PEP-005 activates neutrophils to reduce residual tumor cells

Progress in phase II study of bremelanotide in female sexual dysfunction

MBX-2044 begins proof-of-concept phase IIa study for diabetes

Heplisav begins pivotal phase III study for hepatitis B

Hana requests SPA for pivotal Marqibo study in ALL

Altus and Genentech sign agreement for ALTU-238

Kosan and Pfizer sign worldwide license agreement for motilin agonist program

Enrollment completed in phase II study of faropenem for acute otitis media

APF-530 NDA filing delayed

EndoTAG-1 shows good safety and preliminary efficacy in pancreatic cancer

Proellex improves bleeding and pain in uterine fibroid patients

NCI begins new studies of ispinesib

iCo files IND for iCo-007 for the treatment of eye diseases

Tibotec files to begin phase I testing of HCV NS3/4A protease inhibitor

GSK to acquire Praecis

NS-2359 begins phase II development for major depressive disorder

Panacos files IND for second-generation HIV maturation inhibitor PA-1050040

Safety, tolerability and efficacy of single- and multiple-dose norclozapine shown in phase II trials

L-type calcium channel modulator MEM-1003 enhances cognitive activity in rodents

Mycamine sNDA filed for candidemia and Candida infections

New agents for cancer covered in recent patent literature

Approvable letter for Altabax in secondarily infected traumatic lesions

Xcytrin filed for NSCLC patients with brain metastases

Byetta receives FDA approval

Recent patents report novel therapeutic agents for asthma, allergy, etc.

Junovan NDA accepted for review

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 28, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 28, 2026.
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Muted and missing M&As: JPM deals absent in 2026
BioWorld
For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...